Recro Gainesville, the CDMO subsidiary of Recro Pharma, has expanded its Georgia manufacturing facility. (Recro Pharma)
Recro Pharma was granted a March 2019 PDUFA date for its non-opioid pain drug after providing the FDA with additional data and answering manufacturing questions raised in a complete response letter. While it awaits the outcome, it is leaning heavily on its CDMO business and that arm of the operation has just completed an expansion that should help the drug developer boost its revenues.
Recro Gainesville, its CDMO subsidiary, has added a 24,000-square-foot facility that includes high-potent material processing space. The new facility sits near its existing 97,000-square-foot solid dose facility in Gainesville, Georgia.